TLDR
- HIMS stock is up 7% in premarket Thursday, extending a 10% gain from Wednesday and putting it on track for a fourth straight day of gains
- The stock has rallied 64% this week — its best weekly performance on record
- The surge was sparked by a partnership deal with Novo Nordisk, allowing HIMS to sell FDA-approved Ozempic and Wegovy on its platform
- Barclays raised its price target from $25 to $29 with an “overweight” rating; Bank of America upgraded from “underperform” to “neutral” with a target of $23
- Q4 EPS came in at $0.08, beating the $0.02 estimate, though revenue of $617.8M slightly missed the $619.5M consensus
Hims & Hers Health (HIMS) had a week it won’t forget. The stock is up roughly 7% in premarket trading on Thursday, following a 10% jump on Wednesday. That makes four straight sessions of gains.
Hims & Hers Health, Inc., HIMS
Through Wednesday’s close, HIMS has surged 64% this week. That’s its best weekly performance on record.
The rally started Monday when news broke that Novo Nordisk plans to distribute its weight-loss drugs through the Hims & Hers platform. The deal clears a legal overhang that had been hanging over the stock.
Under the agreement, Hims & Hers can now sell FDA-approved Ozempic and Wegovy directly to customers through its digital health platform. Analysts have called this a direct revenue and margin driver.
HIMS stock traded at $26.17 during midday Wednesday, up $2.70 on the day, with volume hitting 51.6 million — well above its average of 33.3 million.
Analyst Upgrades Roll In
The Novo Nordisk deal triggered a wave of analyst moves. Barclays raised its price target from $25 to $29, keeping an “overweight” rating. That implies about 10.8% upside from current levels.
Bank of America upgraded HIMS from “underperform” to “neutral” and lifted its target from $12.50 to $23. Deutsche Bank raised its target from $25 to $28, maintaining a “hold” rating.
The overall consensus from MarketBeat sits at “Hold” with a price target of $30.75. Three analysts rate it a Buy, thirteen say Hold, and one has a Sell.
The stock also saw unusually large options activity, with around 322,000 call contracts traded — a sign of strong bullish positioning that can amplify upside moves.
Q4 Earnings and Buyback
HIMS reported Q4 earnings on February 23. EPS came in at $0.08, well ahead of the $0.02 analyst estimate. Revenue was $617.8 million, just shy of the $619.5 million consensus.
Revenue was still up 28.4% year-over-year. The company posted a return on equity of 22.48% and a net margin of 5.47%.
The board also approved a $250 million stock buyback plan, covering about 3% of outstanding stock. Buyback authorizations typically signal that management believes the stock is undervalued.
Looking ahead, analysts expect full-year EPS of $0.29 for the current year.
The stock’s 52-week range is $13.74 to $70.43. At Wednesday’s close, it sits well above its 50-day moving average of $24.31 but still below its 200-day average of $37.75.
Despite the week’s gains, short interest remains a watch item. Analysts have flagged squeeze dynamics as a source of volatility — gains driven by short covering can reverse quickly once speculative pressure fades.
Institutional investors currently own 63.52% of HIMS stock. Insiders hold 17.71%, though insiders sold 80,463 shares in the last quarter.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
